Loading…
Loading…
AS does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for AS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for AS and 80,000+ other tickers.
See exactly how AS's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for AS and 80,000+ other tickers.
Amer Sports, Inc. is a global enterprise dedicated to the creation, production, promotion, and sale of athletic equipment, clothing, footwear, and related accessories. The company's extensive reach covers Europe, the Middle East, Africa, the Americas, China, and the wider Asia Pacific region. Its operations are structured into three main divisions. The Technical Apparel segment focuses on high-performance outdoor wear, shoes, and accessories, primarily under the Arc'teryx and Peak Performance brands. The Outdoor Performance segment supplies a variety of outdoor apparel, footwear, accessories…
Investors interested in stocks from the Leisure and Recreation Products sector have probably already heard of Academy Sports and Outdoors, Inc. (ASO) and Amer Sports, Inc. (AS). But which of these two companies is the best option for those looking for undervalued stocks?
SKYRIZIÂ (risankizumab) and RINVOQÂ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2
The disposition involved ~117,000 shares for a total value of $3.1 million. Traded shares represented 78% of the equity stake held directly before the filing.
New SKYRIZIÂ (risankizumab-rzaa) and RINVOQÂ (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseasePR NewswireNOR
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressPR Newsw